Free tool
Oncology stocks
We cover 22 companies grouped under the Oncology theme. The median market value in the group is $4.08B. Across the group, the median move over the past trading day is +1.92%. 86% of the 22 with a 200-day average trade above it. Price change over the past year runs from +11.9% to +471.5% across the middle 80 percent of the group, with a median of +164.6%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
22 of 319 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return | Next report |
|---|---|---|---|---|---|---|
| 6MK.DE | Merck & Co., Inc. | 129.28 EUR | +11.62% | +44.70% | +83.96% | Oct 29, 2026 |
| MRK | Merck & Co., Inc. | $156.45 | +19.65% | +48.06% | +88.17% | Oct 29, 2026 |
| AZN.L | AstraZeneca PLC | 12,110.00 GBP | −6.41% | −10.89% | +1.98% | Oct 30, 2026 |
| AZN | AstraZeneca PLC | $169.66 | +0.01% | −6.39% | +7.60% | Oct 30, 2026 |
| 4528.T | Ono Pharmaceutical Co., Ltd. | 2,511.00 JPY | +3.89% | +16.57% | +62.22% | Oct 29, 2026 |
| LNTH | Lantheus Holdings, Inc. | $100.87 | −6.63% | +49.95% | +79.61% | Nov 5, 2026 |
| COGT | Cogent Biosciences, Inc. | $36.80 | −9.00% | +5.93% | +212.13% | Nov 3, 2026 |
| ERAS | Erasca, Inc. | $17.76 | −5.88% | +394.71% | +1016.98% | Nov 11, 2026 |
| RLAY | Relay Therapeutics, Inc. | $20.57 | +10.35% | +151.47% | +486.04% | Nov 5, 2026 |
| CELC | Celcuity Inc. | $92.27 | +12.16% | −8.23% | +87.35% | Nov 11, 2026 |
| TNGX | Tango Therapeutics, Inc. | $24.51 | −8.27% | +174.47% | +264.73% | Nov 4, 2026 |
| RCUS | Arcus Biosciences, Inc. | $31.57 | +13.40% | +35.55% | +211.03% | Oct 27, 2026 |
| IMNM | Immunome, Inc. | $29.39 | +30.14% | +41.14% | +196.22% | Nov 5, 2026 |
| ZLAB | Zai Lab Limited | $26.17 | +40.40% | +51.01% | −23.10% | Nov 5, 2026 |
| SLS | SELLAS Life Sciences Group, Inc. | $14.09 | +29.98% | +223.91% | +637.70% | Nov 11, 2026 |
| NRIX | Nurix Therapeutics, Inc. | $26.95 | +15.02% | +49.22% | +178.70% | Oct 8, 2026 |
| NUVB | Nuvation Bio Inc. | $7.10 | +6.61% | −17.25% | +146.53% | Nov 2, 2026 |
| URGN | UroGen Pharma Ltd. | $46.36 | +11.82% | +104.14% | +150.59% | Nov 5, 2026 |
| XNCR | Xencor, Inc. Common Stock | $29.30 | +47.53% | +96.38% | +265.79% | Nov 4, 2026 |
| NANO.PA | Nanobiotix S.A. | 34.14 EUR | +3.96% | +79.68% | +341.09% | Sep 29, 2026 |
| NBTX | Nanobiotix S.A. | $41.51 | +3.31% | +87.57% | +321.42% | Sep 29, 2026 |
| NVCR | NovoCure Limited | $17.62 | +3.46% | +34.30% | +50.60% | Oct 29, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.